Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

LaBarre Michael J.

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/3/2020

3. Issuer Name and Ticker or Trading Symbol

HALOZYME THERAPEUTICS, INC. [HALO]

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY ROAD

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
SVP, Chief Technical Officer /

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	154223	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to Purchase Common Stock	2/3/2012 ⁽¹⁾	2/3/2021	Common Stock	40000	$7.14	D
Option to Purchase Common Stock	2/2/2013 ⁽¹⁾	2/2/2022	Common Stock	40000	$11.29	D
Option to Purchase Common Stock	2/4/2014 ⁽¹⁾	2/4/2023	Common Stock	55000	$6.55	D
Option to Purchase Common Stock	2/6/2015 ⁽¹⁾	2/6/2024	Common Stock	37500	$13.10	D
Option to Purchase Common Stock	2/4/2016 ⁽¹⁾	2/4/2025	Common Stock	34000	$13.81	D
Option to Purchase Common Stock	2/3/2017 ⁽¹⁾	2/3/2026	Common Stock	78452	$8.11	D
Option to Purchase Common Stock	2/22/2018 ⁽¹⁾	2/22/2027	Common Stock	56352	$12.07	D
Option to Purchase Common Stock	2/14/2019 ⁽¹⁾	2/14/2028	Common Stock	40489	$18.41	D
Option to Purchase Common Stock	7/2/2019 ⁽¹⁾	7/2/2028	Common Stock	2000	$16.78	D
Option to Purchase Common Stock	2/12/2020 ⁽¹⁾	2/12/2029	Common Stock	60146	$16.65	D
Restricted Stock Unit	2/3/2017 ⁽²⁾	⁽²⁾	Common Stock	11559	⁽²⁾	D
Restricted Stock Unit	2/22/2018 ⁽²⁾	⁽²⁾	Common Stock	17606	⁽²⁾	D
Restricted Stock Unit	2/14/2019 ⁽²⁾	⁽²⁾	Common Stock	17314	⁽²⁾	D
Restricted Stock Unit	2/12/2020 ⁽²⁾	⁽²⁾	Common Stock	31532	⁽²⁾	D

Explanation of Responses:
(1)	This option vests one-fourth on such date and then vests 1/48th monthly thereafter.
(2)	One-fourth of the original grant vests on such date and one-fourth vests annually thereafter. Represents a restricted stock unit award with no exercise price.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
LaBarre Michael J. C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY ROAD SAN DIEGO, CA 92121			SVP, Chief Technical Officer